Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort-Reference-Cited by-同舟云学术

Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: Results from a large patient cohort

Published:2013-06 Issue:9 Volume:49 Page:2134-2142
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Iacovelli Roberto,Cartenì Giacomo,Sternberg Cora N.,Milella Michele,Santoni Matteo,Di Lorenzo Giuseppe,Ortega Cinzia,Sabbatini Roberto,Ricotta Riccardo,Messina Caterina,Lorusso Vito,Atzori Francesco,De Vincenzo Fabio,Sacco Cosimo,Boccardo Francesco,Valduga Francesco,Massari Francesco,Baldazzi Valentina,Cinieri Saverio,Mosca Alessandra,Ruggeri Enzo Maria,Berruti Alfredo,Cerbone Linda,Procopio Giuseppe

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Novel approaches in the therapy of metastatic renal cell carcinoma;Lam;World J Urol,2005

2. Recent progress in the management of advanced renal cell carcinoma;Garcia;CA Cancer J Clin,2007

3. Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study;Harshman;Lancet Oncol,2012

4. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma;Dudek;Cancer,2009

5. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases;Porta;BJU Int,2011

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimal sequential therapy using tyrosine kinase inhibitors as the 1st-line treatment in patients with metastatic renal cell carcinoma: A nationwide multicenter study;Asian Journal of Urology;2023-03

2. An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives;Therapeutics and Clinical Risk Management;2022-06

3. Therapeutic sequencing in the era of first-line immune checkpoint inhibitor combinations, a novel challenge in patients with metastatic clear-cell renal cell carcinoma;Bulletin du Cancer;2022-05

4. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study;European Urology;2021-12